Type-I interferon pathway and DNA damage accumulation in peripheral blood of patients with psoriatic arthritis

Front Immunol. 2023 Dec 6:14:1274060. doi: 10.3389/fimmu.2023.1274060. eCollection 2023.

Abstract

Objectives: The abnormal DNA damage response is associated with upregulation of the type-1 interferon (IFN-I) pathway in certain rheumatic diseases. We investigated whether such aberrant mechanisms operate in psoriatic arthritis (PsA).

Methods: DNA damage levels were measured by alkaline comet assay in peripheral blood mononuclear cells from 52 PsA patients and age-sex-matched healthy individuals. RNA expression of IFIT1, MX1 and IFI44, which are selectively induced by IFN-I, was quantitated by real-time polymerase chain reaction and their composite normalized expression resulted in IFN-I score calculation. RNA expression of IL1β, IL6, TNF, IL17A and IL23A was also assessed in PsA and control subgroups.

Results: In PsA, DNA damage accumulation was increased by almost two-fold compared to healthy individuals (olive tail moment arbitrary units, mean ± SD; 9.42 ± 2.71 vs 4.88 ± 1.98, p<0.0001). DNA damage levels significantly correlated with serum C-Reactive-protein and IL6 RNA expression in PBMCs. Despite increased DNA damage, the IFN-I score was strikingly lower in PsA patients compared to controls (-0.49 ± 6.99 vs 4.24 ± 4.26; p<0.0001). No correlation was found between IFN-I pathway downregulation and DNA damage. However, the IFN-I score in a PsA subgroup was lower in those patients with higher IL1β expression, as well as in those with higher TNF/IL23A PBMCs expression.

Conclusion: DNA damage in PsA correlates with measures of inflammation but is not associated with the IFN-I pathway induction. The unexpected IFN-I downregulation, albeit reminiscent to findings in experimental models of spondyloarthritis, may be implicated in PsA pathogenesis and explained by operation of other cytokines.

Keywords: DNA damage; IL-1; IL-6; PBMC (peripheral blood mononuclear cells); psoriatic arthritis; type-I Interferon.

MeSH terms

  • Arthritis, Psoriatic* / pathology
  • DNA Damage
  • Humans
  • Interferon Type I* / metabolism
  • Interleukin-6 / metabolism
  • Leukocytes, Mononuclear / metabolism
  • RNA / metabolism

Substances

  • Interferon Type I
  • Interleukin-6
  • RNA

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.